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CASE  REPORT
Introduction
The predominant symptom in patients with acute
promyelocytic leukemia (APL) is bleeding diathesis
(> 85%) with laboratory findings of disseminated
intravascular coagulation (DIC). The high morbidity
and mortality come from hemorrhagic complica-
tions.1–3 Past studies have revealed that fatal intracranial
hemorrhage (40%) is the leading cause of death from
cytotoxic chemotherapy, and that the complete
remission rate in APL patients is low,4 although current
treatment that combines all-trans-retinoic acid (ATRA)
and conventional chemotherapy has much improved
the prognosis.
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Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML) and is rare in children
(< 10% of childhood AML). It tends to bleed with disseminated intravascular coagulation (DIC) and intracranial
hemorrhage complication is often fatal. We report a 12-year-old child with APL who suffered a subdural hemorrhage
and initially presented with a subtle headache mistaken as the side effect of all-trans-retinoic acid (ATRA). Blood
component therapy and a pediatric dosage of ATRA (25 mg/m2/day) combined with idarubicin as induction
chemotherapy were administered in the first week, but the bleeding diathesis persisted and DIC profiles showed
no improvement. The patient then developed photophobia, neck stiffness, and constant headache. Evidence of
increased intracranial pressure (IICP) and persistent bleeding from previous venous puncture sites were also noticed
clinically. DIC and life-threatening IICP were beyond control until the ATRA dosage was increased to adult levels
(45 mg/m2/day). This case suggests that the ATRA dosage for pediatric APL patients must be modified according
to clinical condition. Emergency brain imaging should be considered in APL patients with signs of IICP to distinguish
intracranial lesions from ATRA complications. [J Chin Med Assoc 2005;68(9):437–440]
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ATRA is known to have more frequent adverse
effects in pediatric patients. Thus, the optimal dosage
suggested in most pediatric series is 25 mg/m2/day.5
However, this dosage is not always adequate. We
report a pediatric case of APL with life-threatening
subdural hemorrhage (SDH) secondary to DIC who
responded poorly to ATRA until an adult dosage of
45 mg/m2/day was administered.
Case Report
A 12-year-old boy without a significant medical history
was referred to our hospital in December 2003 with
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easy fatigability, decreased appetite, and easy bruising
in all 4 limbs for 2 weeks. Initial laboratory data
obtained at a local hospital included leukocyte count
(1,420/mm3), hemoglobin (7.5 g/dL), platelet count
(8,000/μL), and differential white blood cell (WBC)
counts (myeloblasts, 6%; myelocytes, 5%; pro-
myelocytes, 7%).
On admission, the patient complained of general
weakness and mild headache for 2 days, without
vomiting. Physical examination showed stable vital
signs and some ecchymoses over the face, trunk and
limbs. There was a large hematoma over the right
forearm. Neither hepatosplenomegaly nor
lymphadenopathy were noted. Bone marrow
examination revealed more than 70% hypergranular
promyelocytes. Cytogenetic study showed 46,XY,der
(15)t(15;17)(q22;q11.2) 45,XY,-11,t(15;17)(q22;
q11.2). He was diagnosed as having APL. Laboratory
tests showed a prolonged prothrombin time (PT; 16
seconds) and activated partial thromboplastin time
(aPTT; 47 seconds), the presence of D-dimer, a fibrin-
ogen concentration of 92 mg/dL, and a concen-
tration of fibrin degradation products of 160 μg/mL,
all of which were compatible with DIC.
Platelets, fresh frozen plasma and cryoprecipitate
were infused, but bleeding from the venous puncture
sites persisted. Intravenous fluid hydration and diuretics
were given. ATRA was given orally twice daily at
25 mg/m2/day. Intravenous idarubicin 9 mg/m2 for
3 consecutive days and intrathecal (IT) chemotherapy
with methotrexate were prescribed on the day of
admission according to the Taiwan Pediatric Oncology
Group protocol TPOG APL 2001. During IT
chemotherapy, the patient complained of mild but
tolerable neck pain while keeping in the knee-chest
position. The cerebrospinal fluid was clear in
appearance and cytology revealed 1 WBC/high-
power-field (HPF) and 860 red blood cells/HPF;
traumatic tapping was considered at that time. The
neck pain disappeared after IT chemotherapy and the
clinician did not check the eye fundus to rule out
increased intracranial pressure (IICP).
On the day after IT chemotherapy, the patient
complained of constant headache. Physical examination
revealed neck stiffness. Tracing his history, the patient
remembered that his head was hit against the wall 1
week prior to this admission when he fought with a
classmate. However, there were no specific symptoms
initially. Brain computed tomography (CT) was
arranged on suspicion of an intracranial lesion and
disclosed left frontotemporoparietal SDH (Figure 1A).
Subsequently, photophobia developed and elevation
of blood pressure and decreased heart rate were noted,
compatible with IICP. New ecchymoses were found
over the trunk and limbs. Bleeding from the insertion
site of the neck central venous catheter also persisted.
Conservative medical therapy was suggested by the
neurosurgeon instead of surgical decompression
because of the obvious bleeding tendency. In addition
to vigorous blood component transfusion, the dosage
of ATRA was adjusted to 45 mg/m2/day 1 week later
because of the prolonged PT and aPTT. Mannitol was
given to reduce intracranial pressure. Fortunately,
after 2 weeks of strengthened therapy, DIC was con-
trolled with gradual normalization of DIC profiles and
cessation of bleeding. The headache and photophobia
also subsided.
Bone marrow examination revealed partial remis-
sion in the third week and complete remission in
the seventh week after a second course of idarubicin.
Follow-up brain CT demonstrated obvious improve-
ment of SDH (Figure 1B and 1C). At the time of
writing, the patient was on maintenance therapy and
well without complications.
Discussion
The use of ATRA to treat APL, especially in
combination with chemotherapy, in patients with
coagulopathy has improved the survival rate.6–8 The
major side effect of ATRA is retinoic acid syndrome,
which includes fever, leukocytosis, dyspnea, weight
gain and pleural effusion. Another complication is
pseudotumor cerebri, a syndrome of IICP that can
produce headache, vomiting, blurred vision, and
papilledema. This complication is reportedly more
common in pediatric patients than adults.9–11 As ATRA
has more side effects in children, the AML-BFM study
group suggested that 25 mg/m2/day was a rational
pediatric dosage.5 However, our patient responded
poorly to this dosage. On the contrary, his coagulopathy
improved and clinical bleeding was controlled by
increasing the ATRA dosage to an adult level of
45 mg/m2/day.
Another concern is to recognize IICP secondary to
SDH, which might mimic the manifestation of
pseudotumor cerebri associated with ATRA. This
patient had a clinical picture of DIC with persistent
bleeding in the first week, and the initial manifestation
of his SDH was persistent headache, which was difficult
to differentiate from the side effect of ATRA. However,
neck stiffness became evident later and emergency
brain CT confirmed the diagnosis of SDH. Therefore,
when subtle headache occurs in a child with APL and
DIC, the differential diagnosis of intracranial
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hemorrhage should be taken into consideration. The
authors would like to remind every pediatrician caring
for hematology patients to be aware that minor previous
trauma may cause an immense intracranial hemorrhage
in APL patients with coagulopathy.
We found that laboratory data including PT and
aPTT and clinical bleeding signs improved
dramatically by increasing the ATRA dosage from 25
to 45 mg/m2/day. Therefore, we suggest modifying
the ATRA dosage for children with APL according to
clinical condition. In some situations, an adult dosage
of 45 mg/m2/day is appropriate, especially for patients
who have received ATRA 25 mg/m2/day for more
than 3 days without improvement in PT and aPTT.
However, further study of the pharmacodynamic
differences of ATRA between adult and pediatric
patients, including serum levels of ATRA and drug
interactions, is warranted.
In conclusion, the combination of an adult dose of
ATRA 45 mg/m2/day and chemotherapy with
idarubicin can be prescribed for pediatric APL patients
with severe DIC and bleeding complications including
SDH. Emergency brain CT is indicated for APL
patients with IICP signs to distinguish intracranial
hemorrhage from complications of ATRA.
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Figure 1. (A) Axial computed tomography (CT) of the brain
reveals acute subdural hemorrhage (SDH) over the left fronto-
temporoparietal region with slight mass effect. (B) After 2
weeks, CT scan reveals left temporoparietal subdural effusion
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further 1 month, axial CT of the brain reveals nearly no sub-
dural effusion.
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